Notice for sotrovimab (GlaxoSmithKline Australia Pty Ltd)
Active ingredients
sotrovimab
Date of review outcome
Lapse date
Type
Provisional approval
Indication
Indicated for the treatment of patients with coronavirus disease 2019 (COVID-19) who are at risk for progression to hospitalisation or death
Therapeutic area
Infectious diseases